ITGA4:ITGB1 binds natalizumab

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Integrins are the receptors that mediate cell adhesion to the extracellular matrix (ECM). They are involved in cell adhesion and recognition in a variety of processes including embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells. Integrin alpha-4 (ITGA4) is a receptor for fibronectin. ITGA4 functions as a heterodimer of an alpha subunit and the beta subunit of either the beta-1 chain or the beta-7 chain (ITGA4:ITGB1 shown here).

Natalizumab (Tysabri) is a humanised monoclonal antibody against the cell adhesion molecule α4-integrin. It is a medication used to treat multiple sclerosis and Crohn's disease (No authors 2004). It binds to the α4-subunit of α4b1 and α4b7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptors. This is thought to reduce the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier (Rice et al. 2005).
Literature References
PubMed ID Title Journal Year
15851719 Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale

Hartung, HP, Calabresi, PA, Rice, GP

Neurology 2005
Orthologous Events
Cite Us!